Announced
Completed
Financials
Tags
Biotechnology
Private
biotechnology
United States
Acquisition
Completed
Minority
active pharmaceutical ingredients
Private Equity
Synopsis
Carlyle Group acquired a minority stake in Ambio, a fast-growing global peptide active pharmaceutical ingredient contract development and manufacturing organization, from MVM Partners, a British private equity firm. MVM retains a significant interest in Ambio. Financial terms were not disclosed. Ling Yang, a Managing Director of the Carlyle Asia Partners advisory team, said, “Carlyle sees strong growth potential in the peptide API CDMO business, as well as great opportunities in the generic peptide business. Ambio is well positioned to capture these significant growth opportunities by capitalizing on its demonstrated strong technical capabilities and high quality. Its business model offers customer nimbleness and cost advantage. We look forward to leveraging Carlyle’s healthcare network and capital markets knowhow globally and in China to help Ambio in its next phase of growth.”
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.